Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 9, 2003, Pages 568-572

  Kimoto, Masao ^a   Nagasawa, Kohei ^a   Miyake, Kensuke ^b  

^a SAGA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL LINE; CELLULAR DISTRIBUTION; EVIDENCE BASED MEDICINE; GENE TARGETING; GENETIC TRANSFECTION; GRAM NEGATIVE BACTERIUM; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; RHEUMATIC DISEASE; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, SURFACE; GRAM-NEGATIVE BACTERIA; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, CELL SURFACE; SEPSIS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 0242383211     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310015700     Document Type: Article

References (45)

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
2. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291: 1544-7.
3. Bowie A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000; 67: 508-14.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-80.
5. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947-50.
6. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
8. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403-11.
9. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity Science 1999; 284: 1313-8.
10. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
11. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-61.
12. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-9.
13. Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000; 164: 5998-6004.
14. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.
15. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189: 615-25.
16. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-52.
17. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-82.
18. Miyake K, Yamashita Y, Hitoshi Y, Takatsu K, Kimoto M. Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells. J Exp Med 1994; 180: 1217-24.
19. Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol 1995; 154: 3333-40.
20. Miyake K, Shimazu R, Kondo J, Niki T, Akashi S, Ogata H, et al. Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. J Immunol 1998; 161: 1348-53.
21. Burk O, Klempnauer KH. Estrogen-dependent alterations in differentiation state of myeloid cells caused by a v-myb/estrogen receptor fusion protein. EMBO J 1991; 10: 3713-9.
22. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001; 276: 21129-35.
23. Ohnishi T, Muroi M, Tanamoto K. N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide. J Immunol 2001; 167: 3354-9.
24. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, et al. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. 3 Exp Med 2001; 194: 79-88.
25. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-72.
26. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497-504.
27. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002; 3: 354-9.
28. Akashi S, Nagai Y, Ogata H, Oikawa M, Fukase K, Kusumoto S, et al. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol 2001; 13: 1595-9.
29. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000; 275: 2251-4.
30. Kawasaki K, Gomi K, Nishijima M. Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol 2001; 166: 11-4.
31. Muroi M, Ohnishi T, Tanamoto K. MD-2, a novel accessory molecule, is involved in species-specific actions of Salmonella lipid A. Infect Immun 2002; 70: 3546-50.
32. Chan VW, Mecklenbrauker I, Su I, Texido G, Leitges M, Carsetti R, et al. The molecular mechanism of B cell activation by toll-like receptor protein RP-105. J Exp Med 1998; 188: 93-101.
33. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W, Gerondakis S. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 1998; 187: 663-74.
34. Miura Y, Shimazu R, Miyake K, Akashi S, Ogata H, Yamashita Y, et al. RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood 1998; 92: 2815-22.
35. Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, et al. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med 2000; 192: 23-9.
36. Nagai Y, Shimazu R, Ogata H, Akashi S, Sudo K, Yamasaki H, et al. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 2002; 99: 1699-705.
37. Miura Y, Miyake K, Yamashita Y, Shimazu R, Copeland NG, Gilbert DJ, et al. Molecular cloning of a human RP105 homologue and chromosomal localization of the mouse and human RP105 genes (Ly64 and LY64). Genomics 1996; 38: 299-304.
38. Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, et al. B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2593-600.
39. Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997; 156: 111-26.
40. Hayakawa K, Hardy RR, Parks DR, Herzenberg LA. The 'Ly-1 B' cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med 1983; 157: 202-18.
41. + B cells: the Ly-1 B lineage? Annu Rev Immunol 1988; 6: 197-218.
42. Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, et al. RP105-lacking B cells from lupus patients are responsible for the production of immunoglobulins and autoantibodies. Arthritis Rheum 2002; 46: 3259-65.
43. Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, et al. Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis 2001; 60: 1137-40.
44. Koarada S, Tada Y, Kikuchi Y, Ushiyama O, Suzuki N, Ohta A, et al. CD180 (RP105) in rheumatic diseases. Rheumatology (Oxford) 2001; 40: 1315-6.
45. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276: 38044-51.